T. Kuwayama

Effects of 17β-estradiol and progesterone on migration of human monocytic THP-1 cells stimulated by minimally oxidized low-density lipoprotein in vitro

S. Mizutani, K. Tamakoshi, Y. Asada, 1997 .

Effect of ONO‐5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2‐Year Results From the OCEAN Study

T. Spector, S. Boonen, R. Eastell, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Safety and efficacy of the cathepsin K inhibitor ONO‐5334 in postmenopausal osteoporosis: The OCEAN study

T. Spector, S. Boonen, R. Eastell, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.

P. Abrams, P. Radziszewski, C. Chapple, 2014, The Journal of urology.

Pharmacodynamic Effects on Biochemical Markers of Bone Turnover and Pharmacokinetics of the Cathepsin K Inhibitor, ONO‐5334, in an Ascending Multiple‐Dose, Phase 1 Study

Yoshitaka Hashimoto, M. Small, Shinichi Nagase, 2012, Journal of clinical pharmacology.

The Effect of the Cathepsin K Inhibitor ONO‐5334 on Trabecular and Cortical Bone in Postmenopausal Osteoporosis: The OCEAN Study

H. Genant, R. Eastell, T. Fuerst, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women

Yoshitaka Hashimoto, M. Small, Shinichi Nagase, 2013, Journal of Bone and Mineral Metabolism.

Efficacy and safety of the cathepsin K inhibitor, ONO-5334, and alendronate on post-menopausal osteopenia or osteoporosis: 2-year results from the ocean study

T. Spector, S. Boonen, R. Eastell, 2011 .

Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.

Yoshitaka Hashimoto, M. Small, Shinichi Nagase, 2012, British journal of clinical pharmacology.